文献速递白血病

联合BH3模拟物靶向BCL-2与MCL1在急性髓系白血病临床前模型中具有强效活性

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
PubMed 文献 · Leukemia · 2018-09-10

该临床前研究报道新型BCL-2抑制剂S55746与MCL1抑制剂S63845联合在急性髓系白血病(AML)模型中显示协同促凋亡活性,活性依赖caspase和BAX/BAK,优于标准化疗药物,对多种不良风险基因型及化疗耐药原代样本有效,对正常造血祖细胞毒性较低,并在异种移植模型中延长生存、抑制患者来源白血病。

要点

  • S55746联合S63845在AML临床前模型中显示协同促凋亡活性,依赖caspase和BAX/BAK。
  • 联合方案活性优于标准化疗药物,对多种不良风险基因型及化疗耐药原代样本有效。
  • 联合方案对白血病细胞较正常造血祖细胞更有效,并在异种移植模型中延长生存。

核心结论

  • 双BH3模拟物联合靶向BCL-2和MCL1可行、高度协同,并在多种人AML模型中具有活性。
  • 该方法具有强临床潜力,可快速抑制白血病,且较化疗对正常造血前体细胞毒性降低。

研究设计与样本

  • 临床前研究,评估新型BCL-2抑制剂S55746与MCL1抑制剂S63845联合的抗白血病疗效。

主要发现

  • S55746联合S63845显示协同促凋亡活性,活性依赖caspase和BAX/BAK。
  • 联合方案活性优于标准化疗药物联合,并对多种不良风险基因型及化疗耐药AML患者原代样本有活性。
  • 联合方案对白血病细胞较正常造血祖细胞更有效,提示治疗窗。
  • S55746联合S63845在AML异种移植模型中延长生存,并抑制移植小鼠骨髓中患者来源白血病细胞而不抑制正常造血细胞。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Improving outcomes in acute myeloid leukemia (AML) remains a major clinical challenge. Overexpression of pro-survival BCL-2 family members rendering transformed cells resistant to cytotoxic drugs is a common theme in cancer. Targeting BCL-2 with the BH3-mimetic venetoclax is active in AML when combined with low-dose chemotherapy or hypomethylating agents. We now report the pre-clinical anti-leukemic efficacy of a novel BCL-2 inhibitor S55746, which demonstrates synergistic pro-apoptotic activity in combination with the MCL1 inhibitor S63845. Activity of the combination was caspase and BAX/BAK dependent, superior to combination with standard cytotoxic AML drugs and active against a broad spectrum of poor risk genotypes, including primary samples from patients with chemoresistant AML. Co-targeting BCL-2 and MCL1 was more effective against leukemic, compared to normal hematopoietic progenitors, suggesting a therapeutic window of activity. Finally, S55746 combined with S63845 prolonged survival in xenograft models of AML and suppressed patient-derived leukemia but not normal hematopoietic cells in bone marrow of engrafted mice. In conclusion, a dual BH3-mimetic approach is feasible, highly synergistic, and active in diverse models of human AML. This approach has strong clinical potential to rapidly suppress leukemia, with reduced toxicity to normal hematopoietic precursors compared to chemotherapy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Moujalled DM, Pomilio G, Ghiurau C, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia. 2018. PMID: 30214012. doi:10.1038/s41375-018-0261-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。